Dexcel Pharma

What Dexcel Pharma does

Dexcel Pharma is a privately held Israeli specialty pharmaceutical company founded in 1967–1968, headquartered in Or Akiva with manufacturing in Or Akiva and Yokneam and an R&D center in Jerusalem. It develops, manufactures, and commercializes a diversified portfolio across three product lines: branded Rx (innovative and specialty drugs in CNS, dermatology, women's health, oncology, neurology, and psychiatry), OTC (national brands and private-label pharmaceuticals supplied to major US retailers), and generics (established, niche, and first-to-market drugs in Softgel, tablet, ODT, and sachet dosage forms), with more than 5 billion oral-solid dosages produced annually and 150 million+ packs dispensed to patients each year. Its manufacturing sites are approved by the FDA and EMA and operate at cGMP standards, supporting commercial supply to more than 30 markets globally.

The company operates a hybrid go-to-market combining wholly-owned commercial subsidiaries (US via Edenbridge Pharmaceuticals and Dexcel Pharma USA, UK, Germany, Austria, and Singapore) with a distributor and partner network. In Israel, Dexcel holds approximately 20% share of the prescription drug market and maintains complete pharmacy coverage via its field sales force, working directly with Israeli health authorities, health funds, hospitals, and healthcare professionals. In the US, it leads in OTC private-label supply to major retailers and is now expanding into specialty generics following the 2026 FDA approval of Nintedanib Capsules. International partnerships with Gedeon Richter, LEO Pharma, Recordati, Viatris, Boston Scientific, and Mithra extend its branded portfolio reach within Israel.

Beyond generics and OTC, Dexcel has built an innovation platform through wholly-owned subsidiaries: Clexio Biosciences (2018, CNS-focused clinical-stage drug development including muscarinic M1/M4 and NMDA programs), Dexoligo Therapeutics (2021, siRNA therapeutics and oligonucleotides), and Syremis Therapeutics (2025, neuropsychiatric pipeline). It was also the founding investor in Roivant Sciences in 2014. The company is family-controlled under Founder and Executive Chairman Dan Oren, with Co-CEO Uri Oren and Executive Officer Ilan Oren, and operates with 1,200+ employees globally.

Name

Dexcel Pharma

Legal name

Dexcel Pharma Technologies Ltd

Website

https://dexcel.com

Company type

Private

Founded year

1967

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Dexcel Pharma is a privately held Israeli specialty pharmaceutical company that develops, manufactures, and commercializes branded Rx, generics, and OTC products across 30+ markets, supplying approximately 20% of Israel's prescription drugs and major US retailers via subsidiaries and partners.

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (424210)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro industry

PRIMARYHLAIABAD

Oral Solid Dose (OSD) Generics

Healthcare & Life Sciences/Pharmaceuticals/Generic Pharmaceuticals

SECONDARYCRAOAHAA

Prescription Pharmaceutical (Rx) Wholesale Distribution

Consumer Products & Retail/Wholesale, Distribution & Category Management/Health, OTC & Pharmacy Wholesale Distribution

SECONDARYCRADAMAC

OTC Pain Relief & Fever (Analgesics, Anti-inflammatory, Topical Pain Relief)

Consumer Products & Retail/Consumer Packaged Goods (CPG) Manufacturing & Brands/Health & Hygiene OTC Consumer Goods (First Aid, Oral Care, Personal Health)

SECONDARYHLAIAAAN

Pain Management & Anesthesiology Pharmaceuticals

Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

• Generic pharmaceuticals
• Branded prescription drugs
• Over-the-counter medications
• Pharmaceutical manufacturing
• Specialty therapeutics

Headquarters

HQ city

Or Akiva

HQ country

Israel

HQ region

Middle East

Offices8 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Operations, Personnel, Supply Chain, Marketing or Sales

Revenue model

1. Generic Pharmaceuticals: Broad portfolio of established, niche, and first-to-market generic drugs in various dosage forms. The company supplies over 5 billion oral-solid dosages annually to healthcare systems globally.
2. Branded Rx (Prescription Drugs): Innovative and differentiated branded pharmaceuticals for large addressable populations and specialty markets including CNS, dermatology, women's health, oncology, neurology, and psychiatry.
3. OTC (Over-the-Counter): National brands and private-label pharmaceuticals for pain, fever, digestive health, and allergies. Leading player in OTC private label market supplying major US retailers.
4. Biosimilars: Biosimilar products commercialized in the Israeli market under exclusive licensing agreements.

Go-to-market motion2 records

Distribution channels5 records

Marketing channels3 records

Core offering

Dexcel Pharma develops, manufactures, and commercializes generic and innovative pharmaceutical products worldwide across three core product lines: Branded Rx (innovative drugs across CNS, dermatology, women's health, oncology, neurology, and psychiatry), OTC (national brands and private-label pharmaceuticals for pain, fever, digestive health, and allergies supplied to major US retailers and nutraceuticals in Europe), and Generics (established, niche, and first-to-market drugs in Softgel, tablet, ODT, and sachet dosage forms). The company manufactures over 5 billion oral-solid dosages annually at FDA- and EMA-approved facilities, distributing to 30+ markets through wholly-owned subsidiaries and partner networks.

Product overview

Dexcel Pharma is a privately owned pharmaceutical company developing, manufacturing, and commercializing innovative and generic products worldwide. The company operates three main product lines: (1) Branded Rx - innovative and specialty pharmaceuticals across therapeutic areas such as CNS, dermatology, and women's health, developed internally or through partnerships; (2) OTC - national brands and private-label pharmaceuticals for pain, fever, digestive health, and allergies supplied to major US retailers, plus nutraceuticals in Europe; and (3) Generics - a broad portfolio of established, niche, and first-to-market drugs in various dosage forms (Softgel, tablets, ODT, sachets) with over 5 billion units manufactured annually. Key products include Nintedanib Capsules (FDA-approved generic for Idiopathic Pulmonary Fibrosis), Omeprazole DR (first US OTC store-brand PPI), and well-known consumer brands such as Dexamol Cold, Umpedex, and Combodex.

Differentiator

Problem solved

Functional benefit

Brands

• Roivant Sciences: Strategic investment made by Dexcel in 2014 as the first investor
• Clexio Biosciences
• Dexoligo
• Syremis

Products and services

• Branded Rx (Innovative Drugs)
• OTC (Over-the-Counter) Pharmaceuticals
• Generic Pharmaceuticals
• Nintedanib Capsules
• Omeprazole DR First US OTC store-brand PPI (Proton Pump Inhibitor) for the US private-label OTC market.

Quantifiable outcome

• Supply approximately 20% of all prescription drugs consumed in Israel
• +2 more outcomes

Named customers4 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Nine partnerships are on record, tiered core and minor.

• Gedeon RichtercoreStrategic or Co-development PartnerDexcel collaborates with Gedeon Richter for pharmaceutical partnerships in the Israeli market, leveraging combined expertise in pharmaceutical development and commercialization.
• LEO PharmacoreStrategic or Co-development PartnerPartnership with LEO Pharma for pharmaceutical products in Israel, focusing on specialty therapeutic areas.
• RecordaticoreStrategic or Co-development PartnerCollaboration with Recordati for pharmaceutical product distribution and commercialization in Israel.
• ViatriscoreStrategic or Co-development PartnerPartnership with Viatris for pharmaceutical products in the Israeli market.
• Boston ScientificminorStrategic or Co-development PartnerHealthcare partnership for medical products in Israel.
• MithraminorStrategic or Co-development PartnerPartnership for women's health products in Israel.
• Dexoligo TherapeuticscoreStrategic or Co-development PartnerDexcel formed Dexoligo to translate the RNA therapeutics revolution into novel medicines. Dexoligo is building an in-house pipeline of innovative medicines focused on siRNA therapeutics, oligonucleotides, and delivery solutions.
• Clexio BiosciencescoreStrategic or Co-development PartnerDexcel formed Clexio Biosciences to bring innovative medicine for neurological and psychiatric conditions. Clexio is a multi-asset, CNS-first clinical-stage pharmaceutical company with a broad and growing pipeline.
• Syremis TherapeuticscoreStrategic or Co-development PartnerDexcel established Syremis Therapeutics, a clinical-stage biopharmaceutical company developing novel medicines for mental health conditions. The neuropsychiatric pipeline includes muscarinic M1/M4 agonism and next-generation NMDA antagonism programs.

Scale indicators9 records

Recent moves12 records

Expansion highlights5 records

Direct peers

• Perrigo Company: US-listed leader in OTC private-label and generic Rx products; most directly comparable to Dexcel's US OTC private-label and generics franchise, with similar retailer relationships and dosage-form capabilities.
• Amneal Pharmaceuticals: US-based generic and specialty pharmaceutical manufacturer with broad OSD portfolio, private-label OTC exposure, and biosimilar pipeline; comparable scale and channel mix to Dexcel.
• Dr. Reddy's Laboratories: India-headquartered global generic and OTC pharmaceutical company with FDA-approved manufacturing, complex generics, and private-label OTC; similar vertically integrated model and US market focus.
• Endo International: US specialty and generics pharmaceutical company focused on complex generics, sterile injectables, and specialty therapeutic areas including pain; comparable to Dexcel's specialty Rx and complex generics strategy.
• Apotex: Canadian global generic pharmaceutical manufacturer with broad OSD portfolio, FDA-approved facilities, and growing biosimilars presence; comparable vertically integrated generics business.
• Alvogen: US-headquartered specialty generics company with significant presence in Israel via its Alvogen Israel subsidiary; directly comparable therapeutic mix and Israeli market overlap.
• Cipla: India-headquartered global pharmaceutical company with strong generics, OTC, and complex drug delivery portfolio across multiple dosage forms; comparable in manufacturing scale, FDA approvals, and emerging-market reach.

Broad incumbents

• Teva Pharmaceutical Industries: Israel's largest pharmaceutical company and global generics giant; overlaps with Dexcel on generics manufacturing, Israeli market presence, and CNS/specialty therapeutic areas, though at far larger scale.
• Bausch Health Companies: Global pharmaceutical company with significant generics, OTC, and specialty Rx businesses; comparable portfolio breadth in pain, digestive, and allergy categories where Dexcel operates.
• Sandoz (Novartis): Global leader in generic and biosimilar pharmaceuticals with FDA/EMA-approved manufacturing; directly comparable to Dexcel's generics and biosimilars business model at much larger scale.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/dexcelpharma
• LinkedInlinkedin.com/company/dexcel-pharma

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles13 records

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments11 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Dexcel Pharma